Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

October 6, 2021

Study Completion Date

October 6, 2021

Conditions
Sepsis, Severe
Interventions
BIOLOGICAL

CYT107

IV twice a week at 10µg/kg for 3 weeks

DRUG

Placebos

IV twice a week at the same volume for 3 weeks

Trial Locations (10)

21000

CHU Dijon Bourgogne, Dijon

37044

Chru Bretonneau, Tours

45067

Chr Orleans, Orléans

49933

CHU Angers, Angers

63110

Washington University School of Medicine, St Louis

69003

Hôpital Edouard Herriot, Lyon

75014

Hopital COCHIN, Paris

87042

University Hospital of Limoges, Limoges

94300

Hopital HENRI MONDOR, Créteil

32610-0108

University of Florida, Gainesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

University Hospital, Limoges

OTHER

collaborator

Emerald Clinical Inc.

INDUSTRY

lead

Revimmune

INDUSTRY